I'm guessing he means having Missling take an early look-see at the data. I'm with you, though. I'm much less worried about 250 or so ALZ trial participants having statistically significant / clinically meaningful data, than I was 30 Rett or 140 PDD patients, and I held tight through both of those extremely binary events. The payoff for positive ALZ data is through the roof compared to those 2 as well, and even if it isn't as positive as we expect, we have Rett and PDD to fall back on, and ALZ to further explore. Like you, I have concerns with waiting and being effed with by Wall Street and BP.
Market Data 
Markets 
AI
